Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process
Open Access
- 3 February 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1854
Abstract
Atherosclerosis stands out as one of the leading causes of global mortality. The inflammatory response against vascular wall components plays a pivotal role in the atherogenic process. The initiation of this process is notably driven by oxidized low-density lipoprotein (oxLDL) and a range of pro-inflammatory cytokines, with interleukin-1β (Il-1β) and tumor necrosis factor α (TNFα) emerging as particularly significant in the early stages of atherosclerotic plaque formation. In recent years, researchers worldwide have been diligently exploring innovative therapeutic approaches for metabolic diseases, recognizing their impact on the atherogenesis process. Our study aimed to investigate the influence of glucagon-like peptide 1 receptor agonists (GLP-1RA) on cytokine concentrations associated with the initiation of atherosclerotic plaque formation in a group of patients with type 2 diabetes and dyslipidemia. The study encompassed 50 subjects aged 41–81 (mean: 60.7), all diagnosed with type 2 diabetes, dyslipidemia and confirmed atherosclerosis based on B-mode ultrasound. Following a 180-day treatment with dulaglutide or semaglutide, we observed a statistically significant reduction in biochemical markers (oxLDL, TNFα and Il-1β) associated with the initiation of the atherosclerotic process (p < 0.001) within our study group. In addition to the already acknowledged positive effects of GLP-1RA on the metabolic parameters of treated patients, these drugs demonstrated a notable reduction in proinflammatory cytokine concentrations and may constitute an important element of therapy aimed at reducing cardiovascular risk.Keywords
Funding Information
- Medical University of Silesia (PCN-1-227/N/2/O)
This publication has 39 references indexed in Scilit:
- GLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase AJournal of Cardiovascular Pharmacology, 2014
- Exendin‐4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltrationBritish Journal of Pharmacology, 2014
- Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitusDiabetologia, 2013
- Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathwayActa Pharmacologica Sinica, 2013
- Cholesterol Crystals and InflammationCurrent Rheumatology Reports, 2013
- Obesity, inflammation and the immune systemProceedings of the Nutrition Society, 2012
- Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aortaHeart, 2011
- TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failurePharmacology & Therapeutics, 2010
- Exendin-4 Protects β-Cells From Interleukin-1β–Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase PathwayDiabetes, 2008
- Inflammatory Process in Type 2 DiabetesAnnals of the New York Academy of Sciences, 2006